EX-99.1 2 ex99-1.htm

 

 

Sigma Labs Reports Second Quarter 2019 Financial Results

 

Recent Proof of Concept Wins with Major OEM’s and Fortune Global 500 Companies Position Sigma for Commercial Orders

 

SANTA FE, NM - August 14, 2019Sigma Labs, Inc. (NASDAQ: SGLB) (“Sigma Labs”), a leading provider of quality assurance software to the commercial 3D printing industry, reported its financial and operational results for the second quarter ended June 30, 2019.

 

Key Second Quarter 2019 and Subsequent Highlights

 

  Selected by a major international OEM machine manufacturer to deploy two PrintRite3D® quality assurance software programs as part of an evaluation process for a broader rollout.
     
  Selected by Airbus (AIR:FP / OTC: EADSY), a global leader in aeronautics, space and related services to deploy the PrintRite3D version 5.0 software product into a laser powder bed printer as part of a testing and evaluation program ahead of a larger potential commercial rollout throughout the Airbus organization.
     
  Partnered with Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and 3D printing solutions, and as a result of being Sigma’s first RTE installation, entered an agreement to integrate Sigma Labs’ proprietary PrintRite3D software solution into Materialise’s embedded hardware solution.
     
  Launched the breakthrough PrintRite3D® version 5.0 quality assurance software at the RAPID+TCT 3D Printing and Additive Manufacturing Conference in May 2019, a step-change software update featuring real-time melt pool analytics with automated anomaly detection, enabling exciting new industrial-scale applications of the company’s software.
     
  Realized third-party validation of Sigma Labs’ proprietary PrintRite3D® quality assurance software through a Defense Advanced Research Project Agency (DARPA) research study conducted in collaboration with Honeywell Aerospace.
     
  Fortified our balance sheet through a $2.3 million underwritten public offering of common stock in August 2019 to advance commercialization efforts of its proprietary quality assurance software products.
     
  Appointed Frank D. Orzechowski as Chief Financial Officer effective July 1, 2019. The 30-year financial and operational veteran has led large teams through significant corporate transactions, including mergers and acquisitions, financings and other transactions during his career.

 

   
 

 

 

  Presented at multiple investor and industry conferences to strengthen the company’s commercial and investor presence, including:

 

  AeroDef Manufacturing Conference in Long Beach, California;
  RAPID+TCT 2019 Additive Manufacturing Conference in Detroit; and
  9th Annual LD Micro Invitational Investor Conference in Los Angeles, California.

 

Management Commentary

 

“The second quarter of 2019 was highlighted by sustained commercialization efforts, as we continue to make meaningful progress towards integrating our proven quality assurance technology into innovative new applications in the multi-billion-dollar industrial 3D printing market,” said John Rice, Chief Executive Officer of Sigma Labs.

 

“Our focus remains on four key areas:

 

  1. Product Development: Making our proprietary PrintRite3D software increasingly simple to use for our customers and integrating it into exciting new end-user applications, as demonstrated with our version 5.0 which integrated an improved user interface as well as other exciting new capabilities, transforming it into a readily usable software product.
     
  2. Securing New Evaluation Programs: As with our recently announced Airbus partnership to evaluate our PrintRite3D version 5.0 software for a broader rollout, we continue to seek placements with top-tier manufacturers, allowing them to ‘test drive’ our software, demonstrating the clear value and making a wider-scale purchase more likely.
     
  3. Negotiating OEM Transactions: As part of our broader vision for the company, our goal is to have PrintRite3D deployed into the marketplace directly from the factory, coming pre-installed on new machines. We will continue to make a strong push at all the original equipment manufacturers to establish long-term OEM partner agreements to integrate PrintRite3D into their machines, adding value both for Sigma Labs shareholders and their end-customers who will experience better overall manufacturing quality.
     
  4. Preserving Shareholder Value: We recently announced the completion of a $2.3 million public offering of common stock, which fortifies our balance sheet and, through our capital-light operating model and disciplined approach to capital allocation, brings Sigma Labs much closer to a profitable entity. We seek to minimize dilution wherever possible and constantly seek out new ways to build long-term value for our shareholders.

 

“Our core software product, proven out and vetted through case studies with DARPA and Honeywell Aerospace, addresses significant unmet market challenges facing the 3D metal printing industry. I believe we are on the cusp of realizing key operational milestones that position us for a memorable year and look forward to creating long-term value for our shareholders as we continue our steady pace of operational execution.

 

“Given the recent momentum, new CFO appointment, and to increase our transparency with the investor community, we will be returning to a regular cadence of quarterly conference calls commencing with third quarter of 2019 financial results in early November. We look forward to sharing more on our developing story at upcoming industry conferences in Austin, Texas and Frankfurt, Germany and soon to be announced investor conferences in 2019,” concluded Rice.

 

   
 

 

 

Second Quarter 2019 Financial Results

 

Revenue for the second quarter of 2019 decreased 66% to $33,582, as compared to $98,663 in the second quarter of 2018. This decrease is primarily attributable to the 100% dedication of our printer to Internal R&D in the second quarter of 2019 as we accelerated development of the Inspect product, as well as an overall decline in AM revenue.

 

Gross profit in the second quarter of 2019 decreased to negative $27,043, as compared to $30,095, or 30.5% of revenues, in the second quarter of 2018. The decrease in our gross margin is primarily attributable to the additional travel and labor costs associated with the on-site and remote collaboration involved in initiation of the company’s Rapid Test and Evaluation programs.

 

Total operating expenses were $1.6 million in the second quarter of 2019, as compared to $1.4 million in the second quarter of 2018.

 

Net loss in the second quarter of 2019 totaled $1.6 million, or $(0.15) per share, compared to a net loss of $1.4 million, or $(0.25) per share, in the second quarter of 2018.

 

Cash totaled $0.7 million at June 30, 2019, as compared to $1.9 million at March 31, 2019. Subsequent to the closing of the second quarter of 2019, Sigma Labs completed a $2.3 million public offering of common stock.

 

About Sigma Labs

 

Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (CAI) solutions known as PrintRite3D® for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.sigmalabsinc.com.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K (including but not limited to the discussion under “Risk Factors” therein) filed with the SEC on April 1, 2019 and which may be viewed at http://www.sec.gov.

 

Investor Contact:

Chris Tyson

Managing Director

MZ Group - MZ North America

949-491-8235

SGLB@mzgroup.us

www.mzgroup.us

 

   
 

 

 

Sigma Labs, Inc.

Condensed Balance Sheets

(Unaudited)

 

   June 30, 2019   December 31, 2018 
         
ASSETS          
Current Assets:          
Cash  $696,390   $1,279,782 
Accounts Receivable, net   37,982    38,800 
Note Receivable, net   79,875    121,913 
Inventory   570,426    240,086 
Prepaid Assets   68,718    67,255 
Total Current Assets   1,453,391    1,747,836 
           
Other Assets:          
Property and Equipment, net   205,538    277,944 
Intangible Assets, net   510,718    404,978 
Investment in Joint Venture   500    500 
Total Other Assets   716,756    683,422 
           
TOTAL ASSETS  $2,170,147   $2,431,258 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current Liabilities:          
Accounts Payable  $368,055   $217,488 
Notes Payable   50,000    50,000 
Deferred Revenue   78,773    51,498 
Accrued Expenses   271,154    376,833 
Total Current Liabilities   767,982    695,819 
           
TOTAL LIABILITIES   767,982    695,819 
           
Commitments & Contingencies          
           
Stockholders’ Equity          
Preferred Stock, $0.001 par; 10,000,000 shares authorized; None issued and outstanding, respectively   -    - 
Common Stock, $0.001 par; 22,500,000 shares authorized; 10,937,590, and 8,776,629 issued and outstanding, respectively   10,938    8,777 
Additional Paid-In Capital   24,243,575    21,501,407 
Accumulated Deficit   (22,852,348)   (19,774,745)
Total Stockholders’ Equity   1,402,165    1,735,439 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $2,170,147   $2,431,258 

 

   
 

 

 

Sigma Labs, Inc.

Condensed Statements of Operations

(Unaudited)

 

  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
   2019   2018   2019   2018 
                 
REVENUES  $33,582   $98,663   $98,032   $202,078 
                     
COST OF REVENUE   60,625    68,568    157,180    142,363 
                     
GROSS PROFIT   (27,043)   30,095    (59,148)   59,715 
                     
OPERATING EXPENSES:                    
Salaries & Benefits   581,356    426,049    1,093,916    824,706 
Stock-Based Compensation   220,360    423,067    474,566    584,589 
Operating R&D Costs   118,845    95,045    264,117    217,022 
Investor & Public Relations   157,318    103,197    315,107    283,596 
Legal & Professional Service Fees   218,919    177,929    403,489    316,352 
Office Expenses   184,068    110,936    350,178    206,042 
Depreciation & Amortization   49,203    48,253    97,586    95,574 
Other Operating Expenses   38,994    38,035    77,203    71,760 
Total Operating Expenses   1,569,064    1,422,511    3,076,162    2,599,641 
                     
LOSS FROM OPERATIONS   (1,596,107)   (1,392,416)   (3,135,310)   (2,539,926)
                     
OTHER INCOME (EXPENSE)                    
Interest Income   7,016    3,719    12,798    17,086 
State Incentives   -    -    51,877    - 
Exchange Rate Gain (Loss)   (2,264)   1,304    (2,710)   1,304 
Interest Expense   (2,136)   (1,411)   (4,258)   (1,411)
Loss on Disposal of Assets   -    -    -    (36,733)
Total Other Income (Expense)   2,616    3,612    57,707    (19,754)
                     
LOSS BEFORE PROVISION FOR INCOME TAXES   (1,593,491)   (1,388,804)   (3,077,603)   (2,559,680)
                     
Provision for income Taxes   -    -    -    - 
                     
Net Loss  $(1,593,491)  $(1,388,804)  $(3,077,603)  $(2,559,680)
                     
Net Loss per Common Share – Basic and Diluted  $(0.15)  $(0.25)  $(0.31)  $(0.48)
                     
Weighted Average Number of Shares Outstanding – Basic and Diluted   10,777,590    5,572,015    10,063,806    5,286,362 

 

   
 

 

 

Sigma Labs, Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

   Six Months Ended 
   June 30, 2019   June 30, 2018 
OPERATING ACTIVITIES          
Net Loss  $(3,077,603)  $(2,559,680)
Adjustments to reconcile Net Loss to Net Cash used in operating activities:          
Noncash Expenses:          
Depreciation and Amortization   97,586    95,574 
Stock Based Compensation   474,150    594,915 
Loss on Write-off of Asset   -    36,733 
Change in assets and liabilities:          
Accounts Receivable   818    41,028 
Interest Receivable   27,038    38,139 
Inventory   (330,340)   47,100 
Prepaid Assets   (1,463)   (9,613)
Accounts Payable   150,567    187,495 
Deferred Revenue   27,275    34,026 
Accrued Expenses   (105,678)   21,764 
NET CASH USED IN OPERATING ACTIVITIES   (2,737,650)   (1,472,519)
           
INVESTING ACTIVITIES          
Purchase of Property and Equipment   (23,796)   (41,968)
Purchase of Intangible Assets   (107,124)   (60,147)
Payment Received from Notes Receivable   15,000    632,197 
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES   (115,920)   530,082 
           
FINANCING ACTIVITIES          
Proceeds from issuance of Series B Preferred & Warrants   -    1,000,000 
Proceeds from issuance of Series C Preferred & Warrants   -    350,000 
Gross Proceeds from issuance of Common Stock and Warrants   2,521,220    2,040,100 
Less Offering Costs   (326,890)   (443,700)
Proceeds from exercise of Warrants   75,848    - 
NET CASH PROVIDED BY FINANCING ACTIVITIES   2,270,178    2,946,400 
           
NET CHANGE IN CASH FOR PERIOD   (583,392)   2,003,963 
           
CASH AT BEGINNING OF PERIOD   1,279,782    1,515,674 
           
CASH AT END OF PERIOD  $696,390   $3,519,637 
           
Supplemental Disclosures:          
Noncash investing and financing activities disclosure:          
Conversion of Convertible Debt for Stock  $-    (50,000)
Other noncash operating activities disclosure:          
Issuance of Common Stock for services  $153,000   $256,264 
Disclosure of cash paid for:          
Interest  $2,514   $8,761 
Income Taxes  $-   $-